Naturex Receives Approved Urinary Tract Health Claims from Canadian Authorities for Pacran
27 Oct 2014 --- Naturex’s Pacran, the natural solution for urinary comfort, has been awarded a Natural Product Number from Health Canada. This is the 2nd time that Pacran successfully completes a governmental procedure of claim authorization.
Pacran scientific validity as a natural ingredient for urinary health management has recently been recognized by the Canadian Health Authorities. With a minimum daily dose of 500 mg, all finished products using Pacran can make claims such as “helps prevent recurrent urinary tract infections in women” or “used in Herbal Medicine to help prevent (recurrent) urinary tract infections”.
Urinary tract infections (UTI) are a universal problem with nearly half of all women suffering from a UTI at some point in their lives and nearly one in three of those women suffering from recurrent UTI within one year. Formulators are challenged with selecting the right ingredient for their urinary tract health products.
The new approval reinforces the renown of Pacran which already has a Health Functional Food Ingredient Certificate in South Korea, allowing all finished products to claim: “can help urinary tract health by inhibiting adherence of harmful bacteria to urinary tract”.
“The recent health claim approvals from Canada and South Korea independently validate the strength of the scientific substantiation that we’ve built in support of Pacran,” said Dan Souza Sr. Director of Sales and Marketing for Naturex-DBS. “Naturex-DBS will continue to invest in developing gold standard clinical evidence with an eye towards achieving additional Pacran urinary tract health claims around the world.”
Pacran is a 100% all natural full spectrum cranberry ingredient supported by eight efficacy and safety studies. A daily dose of 500 mg of Pacran has been shown to reduce the rate of recurrent UTI, reduce E. coli - the bacteria responsible for 65-85% of UTI –in vivo and deliver E.coli anti-adhesion in ex vivo trials. This evidence drove Pacran’s recent health claim approvals.
